MedTrace Logo

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

NCT02267603 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-07-05

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well pembrolizumab works in treating patients with Merkel cell cancer that cannot be removed by surgery or controlled with treatment, or has spread to other parts of the body. Pembrolizumab may stimulate the immune system to identify and destroy cancer cells.

Conditions

  • Recurrent Merkel Cell Carcinoma
  • Stage III Merkel Cell Carcinoma AJCC v7
  • Stage IIIA Merkel Cell Carcinoma AJCC v7
  • Stage IIIB Merkel Cell Carcinoma AJCC v7
  • Stage IV Merkel Cell Carcinoma AJCC v7

Interventions

OTHER

Laboratory Biomarker Analysis

Ancillary studies

BIOLOGICAL

Pembrolizumab

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Paul Nghiem · Cancer Immunotherapy Trials Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-25
Primary Completion
2018-02-06
Completion
2021-12-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02267603 on ClinicalTrials.gov